Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Classifica tra le azioni #15401
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Prezzo delle azioni
$9.50
Capitalizzazione di mercato
$357.67M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
92.70%
Paese
US
Scambia BioAge Labs Inc. (BIOA)

Categoria

EPS per BioAge Labs Inc. (BIOA)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di BioAge Labs Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per BioAge Labs Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH